MX2015011408A - Antagonistas de il-33 y usos de estos. - Google Patents
Antagonistas de il-33 y usos de estos.Info
- Publication number
- MX2015011408A MX2015011408A MX2015011408A MX2015011408A MX2015011408A MX 2015011408 A MX2015011408 A MX 2015011408A MX 2015011408 A MX2015011408 A MX 2015011408A MX 2015011408 A MX2015011408 A MX 2015011408A MX 2015011408 A MX2015011408 A MX 2015011408A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- antagonists
- protein
- domains
- binding
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 102000017761 Interleukin-33 Human genes 0.000 abstract 7
- 108010067003 Interleukin-33 Proteins 0.000 abstract 7
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona antagonistas de interleucina-33 (lL-33) que comprenden uno o más dominios de unión a IL-33 y uno o más dominios de multimerización y métodos para utilizarlos. De acuerdo con determinadas modalidades de la invención, los dominios de unión a IL-33 pueden comprender una parte de unión a lL-33 de una proteína ST2 y/o una parte extracelular de una proteína lL-1 RAcP. Los antagonistas de lL-33 de la invención son útiles para el tratamiento de enfermedades y trastornos asociados a la señalización de IL-33 y/o la expresión celular de lL-33, como enfermedades infecciosas, enfermedades inflamatorias, enfermedades alérgicas y enfermedades fibróticas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361787121P | 2013-03-15 | 2013-03-15 | |
US201361819029P | 2013-05-03 | 2013-05-03 | |
US201361913417P | 2013-12-09 | 2013-12-09 | |
PCT/US2014/027058 WO2014152195A1 (en) | 2013-03-15 | 2014-03-14 | Il-33 antagonists and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015011408A true MX2015011408A (es) | 2016-04-27 |
MX364591B MX364591B (es) | 2019-05-02 |
Family
ID=50513479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015011408A MX364591B (es) | 2013-03-15 | 2014-03-14 | Antagonistas de il-33 y usos de estos. |
Country Status (12)
Country | Link |
---|---|
US (3) | US9637535B2 (es) |
EP (1) | EP2968454B1 (es) |
JP (1) | JP6404314B2 (es) |
KR (1) | KR20150127591A (es) |
CN (1) | CN105007929B (es) |
AU (1) | AU2014240101B2 (es) |
CA (1) | CA2904377C (es) |
EA (1) | EA034834B1 (es) |
HK (1) | HK1220373A1 (es) |
IL (1) | IL240393B (es) |
MX (1) | MX364591B (es) |
WO (1) | WO2014152195A1 (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
JP6404314B2 (ja) | 2013-03-15 | 2018-10-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−33拮抗薬とその使用法 |
JP6623353B2 (ja) * | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗pd−1抗体並びにその治療及び診断のための使用 |
BR112016013347B1 (pt) | 2013-12-26 | 2023-12-12 | Mitsubishi Tanabe Pharma Corporation | Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos |
SG10201805934RA (en) | 2014-01-10 | 2018-08-30 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
US10040859B2 (en) | 2014-04-21 | 2018-08-07 | The Children's Hospital Of Philadelphia | Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody |
TWI687438B (zh) | 2014-07-03 | 2020-03-11 | 英屬開曼群島商百濟神州生物科技有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
US10428146B2 (en) | 2014-07-22 | 2019-10-01 | Cb Therapeutics, Inc. | Anti PD-1 antibodies |
CN110964108B (zh) | 2014-08-05 | 2023-07-07 | 中美冠科生物技术(太仓)有限公司 | 抗pd-l1抗体 |
US20160168640A1 (en) | 2014-11-10 | 2016-06-16 | Genentech, Inc. | Therapeutic and diagnostic methods for il-33-mediated disorders |
EA201791029A1 (ru) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | Антитела против интерлейкина-33 и их применение |
US20180036404A1 (en) * | 2015-03-02 | 2018-02-08 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
JP6858182B2 (ja) * | 2015-10-06 | 2021-04-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | インターロイキン33(il−33)媒介疾患に関するバイオマーカーおよびその使用 |
US10927155B2 (en) * | 2015-11-19 | 2021-02-23 | George Mason Research Foundation, Inc. | Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta |
CA3011547A1 (en) * | 2016-01-14 | 2017-07-20 | Anaptysbio, Inc. | Inhibition of allergic reaction using an il-33 inhibitor |
BR112018071276A2 (pt) | 2016-04-27 | 2019-02-12 | Pfizer Inc. | anticorpos anti-il-33, composições, métodos e usos dos mesmos |
EP3481393B1 (en) | 2016-07-05 | 2021-04-14 | Beigene, Ltd. | Combination of a pd-1 antagonist and a raf inhibitor for treating cancer |
CN106198953B (zh) * | 2016-07-19 | 2018-06-29 | 重庆医科大学 | 白介素-33在制备诊断肺源性急性肺损伤试剂盒中的用途 |
TWI739887B (zh) | 2016-08-19 | 2021-09-21 | 英屬開曼群島商百濟神州有限公司 | 使用包含btk抑制劑的組合產品治療癌症 |
WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
TW202332696A (zh) * | 2016-12-01 | 2023-08-16 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
CR20190387A (es) | 2017-02-10 | 2019-09-25 | Genentech Inc | Anticuerpos contra triptasa, composiciones de estos y usos de estos |
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
EP3957752A3 (en) | 2017-04-13 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
CN110997725A (zh) | 2017-06-12 | 2020-04-10 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
CN110799543A (zh) | 2017-06-26 | 2020-02-14 | 百济神州有限公司 | 肝细胞癌的免疫治疗 |
KR20210084695A (ko) | 2017-07-06 | 2021-07-07 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
TWI825025B (zh) | 2017-08-31 | 2023-12-11 | 日商田邊三菱製藥股份有限公司 | 包含il-33拮抗劑的子宮內膜異位症治療劑 |
US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
CN111479618B (zh) | 2017-12-22 | 2022-08-02 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
AU2019215363A1 (en) | 2018-01-31 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
KR20230142806A (ko) | 2018-02-09 | 2023-10-11 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
MX2020008988A (es) | 2018-02-28 | 2020-09-28 | Regeneron Pharma | Sistemas y metodos para la identificacion de contaminantes virales. |
JP7315565B2 (ja) | 2018-03-19 | 2023-07-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | マイクロチップキャピラリー電気泳動アッセイおよび試薬 |
IL277890B2 (en) | 2018-04-11 | 2024-03-01 | Regeneron Pharma | Methods for quantification of IL-33 |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
CA3100035A1 (en) | 2018-08-27 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
CN112601963B (zh) | 2018-08-30 | 2024-05-24 | 瑞泽恩制药公司 | 用于表征蛋白质复合物的方法 |
EP3857237B1 (en) | 2019-01-16 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
KR20220007586A (ko) | 2019-05-13 | 2022-01-18 | 리제너론 파마슈티칼스 인코포레이티드 | 개선된 경쟁적 리간드 결합 검정 |
CA3216345A1 (en) | 2019-09-24 | 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
EP4065086A1 (en) | 2019-11-25 | 2022-10-05 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
CA3165060C (en) | 2020-01-21 | 2023-06-20 | Yiming Zhao | Deglycosylation methods for electrophoresis of glycosylated proteins |
KR20220152262A (ko) | 2020-03-13 | 2022-11-15 | 제넨테크, 인크. | 항-인터루킨-33 항체 및 이의 용도 |
WO2021180858A1 (en) | 2020-03-13 | 2021-09-16 | Medimmune Limited | Therapeutic methods for the treatment of subjects with risk alelles in il33 |
EP4132972A1 (en) | 2020-04-06 | 2023-02-15 | MedImmune Limited | Treating acute respiratory distress syndrome with il-33 axis binding antagonists |
JP2023542820A (ja) | 2020-08-31 | 2023-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 細胞培養成績を改善し、アスパラギン配列バリアントを軽減するためのアスパラギン供給戦略 |
KR20230113280A (ko) | 2020-11-25 | 2023-07-28 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 멤브레인 유화법을 사용한 지속 방출 제형 |
MX2023007225A (es) | 2020-12-17 | 2023-06-27 | Regeneron Pharma | Fabricacion de microgeles encapsuladores de proteina. |
JP2024503408A (ja) | 2021-01-20 | 2024-01-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 細胞培養におけるタンパク質力価の改善方法 |
JP2024512299A (ja) | 2021-03-03 | 2024-03-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質の粘度を定量及び変更するためのシステム及び方法 |
BR112023018665A2 (pt) | 2021-03-26 | 2023-10-03 | Regeneron Pharma | Métodos e sistemas para desenvolvimento de protocolos de mistura |
BR112023024984A2 (pt) | 2021-06-01 | 2024-02-20 | Regeneron Pharma | Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit |
WO2023009975A2 (en) * | 2021-07-24 | 2023-02-02 | Anwita Biosciences, Inc. | Fusion proteins comprising suppression of tumorigenicity 2 or interleukin-33, pharmaceutical compositions, and therapeutic applications |
WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
TW202323817A (zh) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Ph建模及控制之系統及方法 |
WO2023059803A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
CN118176167A (zh) | 2021-10-26 | 2024-06-11 | 瑞泽恩制药公司 | 用于产生实验室用水和分配处于不同温度的实验室用水的系统和方法 |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
TW202346856A (zh) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | 分析多肽變體的方法及系統 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1000056A (en) | 1910-11-03 | 1911-08-08 | Carlos Van Bergh | Threshing-machine. |
US1001164A (en) | 1911-06-09 | 1911-08-22 | Arthur W Porter | Cotton-sweep. |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5576191A (en) | 1994-06-17 | 1996-11-19 | Immunex Corporation | Cytokine that binds ST2 |
US20070042978A1 (en) | 2002-12-19 | 2007-02-22 | Jean-Philippe Girard | Nf-hev compositions and methods of use |
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
US7666622B2 (en) * | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
US8865645B2 (en) * | 2006-05-24 | 2014-10-21 | Biogen Idec Ma Inc. | Method of treating lung fibrosis using ST2 polypeptide |
AT502353B1 (de) | 2006-06-29 | 2007-07-15 | Avl List Gmbh | Verfahren und vorrichtung zur konditionierung eines o2-hältigen gases |
US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
US8119771B2 (en) * | 2007-04-26 | 2012-02-21 | The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | Products for altering IL-33 activity and methods thereof |
EP2069784A4 (en) | 2007-05-18 | 2009-11-18 | Medimmune Llc | IL-33 IN INFLAMMATORY DISEASE |
WO2009053098A1 (en) | 2007-10-26 | 2009-04-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of caspase i-dependent cytokines in the treatment of neurodegenerative disorders |
CA2718120A1 (en) * | 2008-03-31 | 2009-10-08 | Genentech, Inc. | Compositions and methods for treating and diagnosing asthma |
ES2655079T3 (es) | 2009-09-10 | 2018-02-16 | Merck Sharp & Dohme Corp. | Uso de antagonistas de IL-33 para tratar enfermedades fibróticas |
US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
UY34813A (es) | 2012-05-18 | 2013-11-29 | Amgen Inc | Proteínas de unión a antígeno dirigidas contra el receptor st2 |
JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
JP6404314B2 (ja) | 2013-03-15 | 2018-10-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−33拮抗薬とその使用法 |
BR112016013347B1 (pt) | 2013-12-26 | 2023-12-12 | Mitsubishi Tanabe Pharma Corporation | Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos |
SG10201805934RA (en) | 2014-01-10 | 2018-08-30 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
-
2014
- 2014-03-14 JP JP2016502323A patent/JP6404314B2/ja active Active
- 2014-03-14 US US14/210,599 patent/US9637535B2/en active Active
- 2014-03-14 WO PCT/US2014/027058 patent/WO2014152195A1/en active Application Filing
- 2014-03-14 EP EP14718264.6A patent/EP2968454B1/en active Active
- 2014-03-14 KR KR1020157022680A patent/KR20150127591A/ko active IP Right Grant
- 2014-03-14 AU AU2014240101A patent/AU2014240101B2/en active Active
- 2014-03-14 EA EA201591331A patent/EA034834B1/ru not_active IP Right Cessation
- 2014-03-14 MX MX2015011408A patent/MX364591B/es active IP Right Grant
- 2014-03-14 CN CN201480013599.0A patent/CN105007929B/zh not_active Expired - Fee Related
- 2014-03-14 CA CA2904377A patent/CA2904377C/en active Active
-
2015
- 2015-08-06 IL IL240393A patent/IL240393B/en active IP Right Grant
-
2016
- 2016-07-18 HK HK16108449.2A patent/HK1220373A1/zh unknown
-
2017
- 2017-03-20 US US15/463,910 patent/US10011647B2/en active Active
-
2018
- 2018-05-29 US US15/991,763 patent/US10774128B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP6404314B2 (ja) | 2018-10-10 |
HK1220373A1 (zh) | 2017-05-05 |
US10774128B2 (en) | 2020-09-15 |
US10011647B2 (en) | 2018-07-03 |
KR20150127591A (ko) | 2015-11-17 |
IL240393A0 (en) | 2015-09-24 |
WO2014152195A1 (en) | 2014-09-25 |
CA2904377C (en) | 2021-07-13 |
CN105007929A (zh) | 2015-10-28 |
US20140271642A1 (en) | 2014-09-18 |
IL240393B (en) | 2019-03-31 |
NZ712651A (en) | 2021-04-30 |
MX364591B (es) | 2019-05-02 |
US20170204158A1 (en) | 2017-07-20 |
AU2014240101A1 (en) | 2015-10-15 |
CA2904377A1 (en) | 2014-09-25 |
EP2968454A1 (en) | 2016-01-20 |
EP2968454B1 (en) | 2019-02-13 |
US20180265567A1 (en) | 2018-09-20 |
CN105007929B (zh) | 2019-05-10 |
US9637535B2 (en) | 2017-05-02 |
JP2016515130A (ja) | 2016-05-26 |
EA201591331A1 (ru) | 2016-01-29 |
AU2014240101B2 (en) | 2018-05-17 |
EA034834B1 (ru) | 2020-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015011408A (es) | Antagonistas de il-33 y usos de estos. | |
PH12015501656A1 (en) | Anti-il-33 antibodies and use thereof | |
PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
PH12015501493A1 (en) | Anti-pdgfr-beta antibodies and uses thereof | |
PH12015502388A1 (en) | Compositions and methods for altering second messenger signaling | |
PH12017500402A1 (en) | Anti-glucagon antibodies and uses thereof | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
AU2019268062A1 (en) | Benzoquinolone inhibitors of VMAT2 | |
MX2018001532A (es) | Anticuerpos anti-angptl8 y usos de estos. | |
PH12015502565B1 (en) | Anti-transferrin receptor antibodies and methods of use | |
UA113129C2 (xx) | ЗЛИТА КОНСТРУКЦІЯ АНТИТІЛО ПРОТИ CD38 З ОСЛАБЛЕНИМ ІНТЕРФЕРОНОМ АЛЬФА-2b | |
EA201491470A1 (ru) | Композиции фактора viii и способы получения и использования подобных | |
SG10201808835QA (en) | Anti-siglec-8 antibodies and methods of use thereof | |
MX2015011409A (es) | Dominios gla como agentes terapeuticos. | |
MX2018013556A (es) | Polipeptidos variantes con rendimiento mejorado y uso de los mismos. | |
MX2019006676A (es) | Anticuerpos anti-ccl2 para el tratamiento de la esclerodermia. | |
MX368669B (es) | Procedimiento para la preparación de 4-amino-1-((1s,4r,5s)-2-fluor o-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-o na. | |
TWD175568S (zh) | 雪鏡(一) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |